Sanofi Ends Trial for E. Coli Shot and Takes a $250 Million Hit
Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an ...
Tackling the threat of drug-resistant E. coli in China
A comprehensive seven-year study across 20 Chinese provinces has revealed a concerning rise in antimicrobial resistance (AMR) ...
pharmaphorum2 天
Sanofi, J&J abandon trial of E coli vaccine after poor data
Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by the problem pathogen Escherichia coli looks ...
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical studyIndependent interim analysis of the E.mbrace phase 3 study finds that ...
GlobalData on MSN2 天
J&J stops Phase III trial of Sanofi’s E. Coli vaccine citing ‘disappointing’ results
The company said it will stop the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over ...
Fierce Biotech2 天
Sanofi takes $250M hit after gamble on J&J E. coli vaccine ends in phase 3 failure
A year and a half after Sanofi swooped in on Johnson & Johnson’s dismantled vaccines unit to pick up an E. coli candidate, ...
PharmiWeb2 天
Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by an independent data monitoring committee (IDMC) determined that Sanofi and Johnson & Johnson’s ...
CBS News on MSN9 天
Foodborne illnesses kill more than 900 Americans each year, researchers find
Foodborne illness costs Americans $75 billion annually in premature deaths, medical care and lost productivity, study finds.
Expert: E. coli infection among doctors at Hong Kong hospital ‘unlikely to spread widely’
An E coli infection linked to the death of a doctor in Princess Margaret Hospital is unlikely to lead to widespread ...
Sanofi to take $250M charge on study failure for E. coli vaccine
The French drugmaker said the vaccine it agreed to develop with Johnson & Johnson a year ago was “not sufficiently effective.
TipRanks on MSN1 天
Sanofi Ends E.coli Vaccine Trial Amid Efficacy Concerns
Sanofi ( ($SNY) ) has provided an announcement. On February 13, 2025, Sanofi announced the discontinuation of the E.mbrace phase 3 study for its ...